Sydney's Innate Immunotherapeutics Ltd. appointed Warwick Tong to the position of chairman.
Tong joined the biotechnology company's board on May 4, after it acquired Amplia Therapeutics Pty Ltd.
Tong's previous roles include CEO of Cancer Therapeutics Cooperative Research Centre and senior positions at GlaxoSmithKline PLC.
Innate Immunotherapeutics develops, makes and sells drugs in Australia and New Zealand.
